ReviewFrontiers in immunology2026
Neutrophil extracellular traps in tumor microenvironment for radiotherapy: friend or foe?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil extracellular traps (NETs) are chromatin-protein complexes released by neutrophils that have dual roles in the tumor microenvironment (TME), participating in anti-tumor immunity and driving malignant progression by promoting tumor proliferation, metastasis, and immune escape. Radiotherapy (RT) exerts anticancer effects by inducing DNA damage and microenvironmental remodeling, but the inflammatory response it triggers can activate the formation of NETs, which exacerbate radioresistance by degrading the extracellular matrix, encapsulating circulating tumor cells, inhibiting CD8+ T-cell infiltration, and promoting distant tumor metastasis. Meanwhile, NETs may act in concert with neutrophils to indirectly enhance radiotherapy efficacy by releasing reactive oxygen species (ROS) and promoting activation and recruitment of tumor-specific T cells. Hypoxia, inflammatory factors, damage-associated molecular patterns (DAMPs), and microbial metabolites in the TME affect radiotherapy outcomes by regulating NET formation. Targeting NETs in combination with radiotherapy reverses immunosuppression and enhances anti-tumoral effects. The functional heterogeneity of NETs subtypes and their spatial and temporal dynamics need to be analyzed in order to optimize individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.